Welcome to our dedicated page for argenx SE American Depositary Shares news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on argenx SE American Depositary Shares stock.
argenx SE (ARGX) is a leading global immunology company dedicated to transforming the lives of individuals suffering from severe autoimmune diseases and cancer. Originating from the Netherlands, argenx focuses on leveraging its advanced antibody engineering technology to address rare and debilitating autoimmune conditions.
One of the company’s landmark achievements is the development and approval of Vyvgart (efgartigimod), a groundbreaking treatment for generalized myasthenia gravis. Vyvgart received approval from the U.S. FDA in December 2021, followed by subsequent approvals in Europe and Japan in 2022. This therapeutic advancement underscores argenx’s commitment to delivering innovative solutions for patients with unmet medical needs.
In addition to Vyvgart, argenx continues to drive forward with several promising projects aimed at expanding its portfolio of antibody-based medicines. The company’s dedication to translating immunology breakthroughs into novel treatments is reflected in its ongoing research and development activities. Notably, argenx is advancing clinical studies on VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with a focus on delivering effective therapies to a broader patient population.
Financially, argenx is well-positioned to sustain its growth trajectory, backed by strategic partnerships and a solid pipeline of innovative products. The company collaborates with key stakeholders across the healthcare industry to enhance its research capabilities and expedite the development of new treatments.
For the latest updates and more detailed information, investors and media can contact:
Ben Petok - BPetok@argenx.com
Alexandra Roy (US) - ARoy@argenx.com
Lynn Elton (EU) - LElton@argenx.com
argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on May 4, 2023, at 2:30 pm CET to discuss its first quarter 2023 financial results and provide a business update. The event will be available via the Investors section of their website. A replay will be accessible for one year. Dial-in numbers are provided for various countries including the U.S., U.K., and Japan.
As a global immunology company, argenx is focused on severe autoimmune diseases and has partnered with researchers through its Immunology Innovation Program. The company is currently evaluating the therapeutic potential of its approved neonatal Fc receptor (FcRn) blocker and advancing several experimental medicines.
argenx SE plans to present six abstracts at the 75th American Academy of Neurology (AAN) Annual Meeting from April 22-27, 2023, focusing on generalized myasthenia gravis (gMG). These presentations will feature clinical and real-world data regarding efgartigimod, an innovative treatment aimed at enhancing outcomes for gMG patients.
The highlights include findings from long-term extension studies of VYVGART® showcasing consistent reductions in IgG antibody levels and improved clinical results. A new analysis will explore the efficacy of efgartigimod in gMG patients early in their disease progression. Additionally, argenx will share insights on expanding patient support programs to address healthcare access challenges.
argenx and Genmab have formed a multiyear collaboration to jointly discover and commercialize novel antibody therapies targeting immunology and oncology. This partnership leverages both companies' expertise in antibody engineering to accelerate the development of treatments for unmet patient needs. The initial focus will be on two differentiated targets: one in immunology and one in cancer. Both companies will share costs and profits from products developed through this collaboration, aiming to unlock new therapeutic candidates that address patient needs more effectively.
FAQ
What is the current stock price of argenx SE American Depositary Shares (ARGX)?
What is the market cap of argenx SE American Depositary Shares (ARGX)?
What does argenx SE specialize in?
What is Vyvgart?
When was Vyvgart approved in the U.S.?
What are argenx's recent projects?
Who can be contacted for more information about argenx?
Where is argenx SE located?
What makes argenx's technology unique?
What is the focus of argenx's R&D?
How does argenx fund its operations?
What is VYVGART Hytrulo?
